Stem Cell Clinic

FASEB announces 2014 Science Research Conference: Skeletal Muscle Satellite and Stem Cells

By Stem Cell Clinic

PUBLIC RELEASE DATE:

22-Jan-2014

Contact: Robin Crawford src@faseb.org 301-634-7010 Federation of American Societies for Experimental Biology

Bethesda, MD This 2014 FASEB Science Research Conference focuses on recent advances in our understanding of the regulatory mechanisms controlling normal and abnormal functions of muscle-resident stem cells in regeneration, muscle homeostasis, hypertrophy, aging and muscle degenerative disease.

Eight plenary sessions and three dedicated poster sessions will encompass the following major themes: transcriptional and posttranscriptional regulation of gene expression in stem cells, satellite cell heterogeneity and potential, stem cell signaling and environmental interactions, satellite cell quiescence, activation and renewal, non-satellite stem cells, satellite cell proliferation, commitment and differentiation, muscle stem cells in growth and hypertrophy, and muscle stem cells in aging, disease and therapeutics.

This FASEB Conference increasingly attracts investigators in related fields who are interested in the rapid advances in muscle stem cell research, and interdisciplinary interactions are an important feature of this meeting. Collectively, this conference, which represents the only international conference that focuses exclusively on muscle satellite and stem cell populations, provides a venue to present cutting edge research, foster discussions, and promote collaborative interactions, with the goal of advancing a fundamental understanding of muscle-resident stem cells, and ultimately, translating this knowledge to the clinic.

###

FASEB has announced a total of 35 Science Research Conferences (SRC) in 2014. Registration opens January 17, 2014. For more information about an SRC, view preliminary programs, or find a listing of all our 2014 SRCs, please visit http://www.faseb.org/SRC.

Since 1982, FASEB SRC has offered a continuing series of inter-disciplinary exchanges that are recognized as a valuable complement to the highly successful society meetings. Divided into small groups, scientists from around the world meet intimately and without distractions to explore new approaches to those research areas undergoing rapid scientific changes.

In efforts to expand the SRC series, potential organizers are encouraged to contact SRC staff at SRC@faseb.org. Proposal guidelines can be found at http://www.faseb.org/SRC.

View post:
FASEB announces 2014 Science Research Conference: Skeletal Muscle Satellite and Stem Cells

stem cell therapy treatment for Right Hemiparesis Cerebral Palsy by dr alok sharma, mumbai, india – Video

By Uncategorized


stem cell therapy treatment for Right Hemiparesis Cerebral Palsy by dr alok sharma, mumbai, india
improvement seen in just 5 days after stem cell therapy treatment for Right Hemiparesis Cerebral Palsy by dr alok sharma, mumbai, india. Stem Cell Therapy do...

By: Neurogen Brain and Spine Institute

More here:
stem cell therapy treatment for Right Hemiparesis Cerebral Palsy by dr alok sharma, mumbai, india - Video

Pluristem stem cell treatment for muscle injury meets main goal

By Stem Cell Treatment

TEL AVIV (Reuters) - Pluristem Therapeutics Inc said results from its early/mid-stage clinical trial indicated its placenta-derived stem cells for the treatment of muscle injury were safe and provided evidence the cells might be effective in treating orthopedic injuries.

"Patients treated with PLX-PAD had a greater improved change of maximal voluntary muscle contraction force than the placebo group," Israel-based Pluristem said in a statement on Tuesday.

The trial was conducted at the Orthopedic Clinic of the Charite University Medical School under the auspices of the Paul-Ehrlich-Institute, Germany's health authority.

"This was a very important study not only for Pluristem but for the cell therapy industry in general," Pluristem chief executive Zami Aberman said. "Based on these results, we intend to move forward with implementing our strategy towards using PLX cells in orthopedic indications and muscle trauma."

The injured muscle studied was the gluteus medius muscle in the buttock. Total hip replacement surgery via the standard transgluteal approach necessitates injury of the gluteus medius muscle, and post-operative healing is crucial for joint stability and function.

"The study showed that PLX-PAD cells were safe and well tolerated," the statement said.

The primary efficacy endpoint of the study was the change in maximal voluntary isometric contraction force of the gluteal muscle six months after surgery.

Efficacy was shown in two groups treated with the cells, with one group receiving a 150 million cell dose displaying a 500 percent improvement over the placebo group. Patients treated with a 300 million cell dose showed a 300 percent improvement over the placebo.

An analysis of the gluteal muscle indicated an increase in muscle volume in those patients treated with PLX-PAD cells versus the placebo group.

(Reporting by Tova Cohen)

See the original post:
Pluristem stem cell treatment for muscle injury meets main goal

Scientists Find That Estrogen Promotes Blood-Forming Stem Cell Function

By Stem Cell Treatment

Contact Information

Available for logged-in reporters only

Newswise DALLAS Jan. 22, 2014 Scientists have known for years that stem cells in male and female sexual organs are regulated differently by their respective hormones. In a surprising discovery, researchers at the Childrens Medical Center Research Institute at UTSouthwestern (CRI) and Baylor College of Medicine have found that stem cells in the blood-forming system which is similar in both sexes also are regulated differently by hormones, with estrogen proving to be an especially prolific promoter of stem cell self-renewal.

The research, published in Nature, raises several intriguing possibilities for further investigation that might lead to improved treatments for blood cancers and increased safety and effectiveness of chemotherapy.

Before the finding, blood-forming stem cells were thought to be regulated similarly in both males and females, according to the papers senior author, Dr. Sean Morrison, Director of CRI, Professor of Pediatrics, and the Mary McDermott Cook Chair in Pediatric Genetics at UTSouthwestern Medical Center.

However, while working in Dr. Morrisons laboratory as postdoctoral fellows, Dr. Daisuke Nakada, the first and co-corresponding author of the study, and Dr. Hideyuki Oguro discovered that blood-forming stem cells divide more frequently in females than in males due to higher estrogen levels. The research, conducted using mice, demonstrated that the activity of blood-forming stem cells was regulated by systemic hormonal signals in addition to being regulated by local changes within the blood-forming system.

This discovery explains how red blood cell production is augmented during pregnancy, said Dr. Morrison. In female mice, estrogen increases the proliferation of blood-forming stem cells in preparation for pregnancy. Elevated estrogen levels that are sustained during pregnancy induce stem cell mobilization and red cell production in the spleen, which serves as a reserve site for additional red blood cell production.

The study involved treating male and female mice over a period of several days with amounts of estrogen needed to achieve a level consistent with pregnancy. When an estrogen receptor that is present within blood-forming stem cells was deleted from those cells, they were no longer able to respond to estrogen, nor were they able to increase red blood cell production. The results demonstrate that estrogen acts directly on the stem cells to increase their proliferation and the number of red blood cells they generate.

If estrogen has the same effect on stem cells in humans as in mice, then this effect raises a number of possibilities that could change the way we treat people with diseases of blood cell-formation, said Dr. Morrison. Can we promote regeneration in the blood-forming system by administering estrogen? Can we reduce the toxicity of chemotherapy to the blood-forming system by taking into account estrogen levels in female patients? Does estrogen promote the growth of some blood cancers? There are numerous clinical opportunities to pursue.

Research support for Dr. Morrison came from the Cancer Prevention and Research Institute of Texas (CPRIT); the National Heart, Lung, and Blood Institute; the Howard Hughes Medical Institute; and donors to Childrens Medical Center Foundation. Dr. Nakada is now a CPRIT Scholar and Assistant Professor of Molecular and Human Genetics at Baylor College of Medicine. The research was initiated in the Life Sciences Institute at the University of Michigan and completed at Baylor College of Medicine and CRI.

Read more:
Scientists Find That Estrogen Promotes Blood-Forming Stem Cell Function

Teen battling rare disease

By Stem Cell Treatment

A YOUNG FOOTBALLER continues to seek help in his fight against a rare blood disease.

Joshua Sobers-Henry and his immediate family are asking for financial assistance as the teenaged goalkeeper looks to head to the United States later this week for stem cell treatment in his battle with aplastic anaemia.

News of Sobers-Henrys rare condition broke on the Barbados Soccer Academys Facebook page as his family and club members continue to appeal to the public for blood donations and monetary assistance.

He has an appointment for Monday in Washington at the National Institute of Health (NIH) in Bethesda, Maryland, where he starts stem-cell treatment for six months so we need as much help as we can get, explained Sobers-Henrys mother Carolann in an interview with MIDWEEKSPORT yesterday.

And even then it all depends on how the body reacts to the treatment because if it doesnt [respond positively] then we have to look at doing a bone marrow transplant.

Aplastic Anaemia is an extremely rare blood disorder in which the bodys bone marrow doesnt make enough new blood cells and if left untreated, has a high risk of death.

At present, Sobers-Henry receives blood transfusions at the Queen Elizabeth Hospital, but his blood type AB positive is not as common as others and isnt always available.

But those transfusions are just temporary as he needs to start stem cell treatment as soon as possible if he is to successfully overcome the disease.

The situation unfolded last November when Sobers-Henry inexplicably started to get regular headaches after playing for both Coleridge and Parry and the St Lucy constituency side.

At first it was thought to be just the flu, but later tests showed positive for the rare blood disorder after his eyes, tongue and finger tips all turned white one day.

Continued here:
Teen battling rare disease

2013: Stem cell research’s new partnership of science and …

By Stell Cell Research

The year just ended saw some major developments in medicine, not the least of which involved the consolidation of trends in the controversial area of stem cell research. And the big news isthat this research is rapidly evolving, in ways quite different from what experts predicted just a decade ago.

Insofar as the general public is aware of stem cells, it is most likely to be of embryonic stem cells. For more than a decade these stem cells obtained by destroying living, human embryos have been heralded for their supposedly miraculous potential to cure any number of diseases and conditions. Celebrities such as Michael J. Fox, Kevin Kline, Mary Tyler Moore, and the late Christopher Reeve all went to Capitol Hill to promote federal funding of such ethically contentious research because, they claimed, it was the research most likely to help millions suffering from disease and disabilities. One prominent senator heralded these cells as a veritable fountain of youth.

But in the time since President George W. Bush first authorized limited federal funding for human embryonic stem cell research (hESCR) in 2001, and especially since President Obama lifted the Bush restrictions in 2009, something very different from these predictions and promises has occurred. Programs established for the express purpose of funding hESCR are more and more directing resources to pursuing adult stem cells and other alternatives, such as induced pluripotent stem cell (iPSC) research.

A look at the California Institute for Regenerative Medicine (CIRM) itself is instructive. Established by voter referendum in 2004, CIRM had an initial mission of giving priority funding to hESCR and Somatic Cell Nuclear Transfer (SCNT), i.e., human cloning for research. CIRMs budget for funding stem cell research was $3 billion over 10 years.

In its first year of funding, 2007, CIRM was true to this mission. In two rounds of grants that year, CIRM funded just over 100 research projects; three involved SCNT and all of the rest went to research involving hESCs.

In 2009, CIRM revised its strategic plan to give funding priority to projects deemed most likely to actually lead to clinical trials and not just to those that involve hESCs. The resulting grants showed a startling turn. In one round of grants, hESCR projects received a total of $35 million in funding, but CIRM now seemed also to embrace the alternatives, as non-hESCR projects received almost as much $33 million.

A subsequent round of grants that year showed an even more dramatic turn away from hESCR. Of 14 grants awarded, only four went to hESCR, totaling $71.5 million. The remaining 10 grants all went to projects involving adult stem cells, iPSCs or other non-embryonic avenues of research and totaled just over $158 million.

Even the media, which so heavily favored hESCR in their reporting and editorials, took note. For 3 1/2 years, the agency focused on the basic groundwork needed to someday use human embryonic stem cells to replace body parts damaged by injury or disease. Such cures are still far in the future, The Los Angeles Times reported. Now the institute has a more immediate goal: boosting therapies that are much further along in development and more often rely on less glamorous adult stem cells.

In something of an irony, little of it is going to the reason the institute exists to work with human embryonic stem cells, the Knight Science Journalism Tracker commented.

And the New York Times characterized this round of grants as a tacit acknowledgment that the promise of human embryonic stem cells is still far in the future.

Read more from the original source:
2013: Stem cell research's new partnership of science and ...

Dr. Burton Feinerman Shares Experiences from Celebrity Care to Modern Medicine

By Uncategorized

TAMPA, Fla. (PRWEB) January 22, 2014

Societys continual, obsessive search for perpetual youth has lead many on a tumultuous path of medical mayhem from shots to creams and a variety of procedures in between.

A leader in modern medicine, Dr. Burton Feinerman has always been at the forefront of new and life changing procedures in the healthcare community. Feinerman's experience includes his time as a key research associate at the Papanicolau Cancer Research Institute in Miami.

His career took a glamorous turn when he became a concierge physician to the stars at his office in Maui, Hawaii. He has treated a variety of high-profile clientele including celebrities Eddie Murphy, Larry David, Pink, Brittney Spears, Nick Nolte, Christian Slater, Arnold Schwarzenegger and Oprah, who once thanked him with an autographed magazine for the shot in the tush.

Staying true to his mission to find relief for those afflicted with incurable diseases, Feinerman soon focused his efforts on the innovative and unfamiliar world of cell regeneration and gene therapy. As one of the original physician scientists to create stem cell protocols for incurable diseases, Feinerman now runs his clinic in Tampa, Fla. where he treats patients with conditions such as Alzheimers, ALS, Autism, brain damage, Cerebral Palsy, Multiple Sclerosis, Spinal Cord Injury, Parkinsonism, Heart Disease, COPD, diabetes, Chronic Kidney Disease, Pulmonary Fibrosis, Tay Sachs, Sandhoff Disease, Stargardt Disease, Huntington Disease, Scleroderma, Lupus, Rheumatoid Arthritis, Crohns Disease, cancer of all types, Macular Degeneration and Retinitis Pigmentosa.

The emerging developments in stem cell therapy, gene therapy, nanotechnology and tissue engineering offer new hope to millions of patients, said Feinerman.

Stem Cells and Sex Wars By: Dr. Burton Feinerman ISBN: 978-1481774789 Available at Amazon, Barnes and Noble and Authorhouse online bookstores.

About the authors A graduate of New York Medical College, Dr. Burton Feinerman also received extensive postgraduate training from Long Island College Hospital and the Mayo Clinic. He served as chief medicine for the U.S. Army, as part of the 98th General Hospital in Germany as well as chairman of medicine at Miami General Hospital, Opa-Locka Hospital, N. Miami General Hospital and chairman of cancer technologies Kids Medical Centers of America. Active in many industry organizations, Feinerman is a member of the Society of Apheresis, the Society of Bone Marrow Blood Transplantation, the International Society for Cellular Therapy, the Society for Cranial Transplantation and Brain Repair, and the Society for Cardiac Translational Therapy. With over 55 years of experience in medical practice, he is currently the president and CEO of Stem Cell Regen Med.

Read the rest here:
Dr. Burton Feinerman Shares Experiences from Celebrity Care to Modern Medicine

Ore. doctor suspended for stem cell treatments | The Columbian

By Stem Cell Doctors

A A

PORTLAND The Oregon Medical Board has issued a rare emergency suspension of a Eugene, Ore., physician's license after the doctor conducted experimental stem cell treatments on patients. The board considers Dr. Kenneth Welker's medical practice an immediate danger to the public.

Welker can appeal the suspension, issued Thursday. He did not return calls from The Associated Press on Friday, nor did the clinic at which he's employed, Oregon Optimal Health.

According to his online biography, Welker is a trained surgeon who quit his practice to pursue alternative medicine in 2007.

In May 2013, the board's suspension order says, Welker injected processed stem cells into the spine of a 62-year-old woman, and was confused when she began to sweat and feel tingling in her extremities.

Stem cells, unlike other cells in the body, have two distinct characteristics. They can renew themselves through cell division, and they are not specialized in the way that muscle cells or brain cells are. Under certain conditions, they can be induced to transform into organ- or tissue-specific cells.

In 1998, researchers discovered how to derive stem cells from human embryos, and in 2006, they determined how to induce some specialized adult cells to take on the genetic characteristics of stem cells. These are called induced pluripotent stem cells, or iPSC.

iPSC have long been used to treat cancers such as leukemia and lymphoma -- it's what doctors are using when they do bone marrow transplants. The cells are being studied for everything from heart disease to diabetes, but it's too soon to know if these approaches are safe or effective.

Advocates of alternative medicine have heaped praise on the possibility of using iPSC to treat a variety of maladies. Texas Gov. Rick Perry, for instance, had stem cells taken from fat in his own body, grown in a lab and then injected into his back and his bloodstream during a 2011 operation to fuse part of his spine.

But scientists have questioned the safety and wisdom of Perry's treatment, especially because it was not part of a clinical trial in which unproven therapies are tested in a way that helps protect patients and advances medical knowledge.

The rest is here:
Ore. doctor suspended for stem cell treatments | The Columbian

→←